|
Definition |
In cases in which RT fails, salvage cryoablation of the prostate (SCAP) has been proposed as an alternative to SRP, as it has a potentially lower risk of morbidity and equal efficacy. However, the very few studies available have shown disappointing results. In a review of the use of SCAP for recurrent cancer after RT, the 5-year BDFS estimates ranged from 50-70%. A durable response can be achieved in ~50% of patients with a pre-SCAP PSA < 10 ng/mL . In a multicentre study reporting the current outcome of SCAP in 279 patients,
the 5-year biochemical recurrence-free survival (BCR-FS) estimate according to the Phoenix criteria was 54.5± 4.9%. Positive biopsies were observed in 15/46 patients (32.6%) who underwent prostate biopsy after SCAP.
A case-matched control study comparing SRP and SCAP was performed in men with recurrent PCa
after RT. The authors compared the oncological outcomes of the two salvage treatment options after mean follow-up periods of 7.8 (SRP group) and 5.5 years (SCAP group). The 5-year BCR-FS was 61% following SRP,significantly better than the 21% detected after SCAP. The 5-year OS was also significantly higher in the SRP group (95% vs.85%).
|